Orgyne Pharmaceuticals (OPC) Private Limited
U24230TG2019OPC135766ActivePrivateUnlisted
Last updated: 2026-06-09
30
Compliance Health · F
3 / 9 signals passed
Orgyne Pharmaceuticals (OPC) Private Limited is a Private Indian company incorporated in 2019 and based in Telangana, India. Orgyne Pharmaceuticals (OPC) Private Limited operates in Pharmaceuticals & Chemicals (NIC 24230) with authorized capital of —. RegisterKaro's Compliance Health Score for the company is 30/100 (grade F), reflecting a weak compliance posture.
Risk FlagsFinancials not yet extracted · awaiting AOC-4 XBRLDirectors not yet extracted · awaiting MGT-7Health F · 30/100
Revenue (latest FY)
—
Awaiting extraction
PAT (latest FY)
—
Awaiting extraction
Open Charges
0
No encumbrances
Active Directors
0
No resignations
Paid-up Capital
—
—
Filings on Record
0
All current
Incorporated
2019
7 years old
State
Telangana
Sector
Pharmaceuticals & Chemicals
NIC 24230
Class
Private
Sub-category
—
Authorized Capital
—
Paid-up Capital
—
Members
—
Last AGM
—
Last Balance Sheet
—
Latest Filing
—
Registered Email
—
Registered Office
—
ORGYNE PHARMACEUTICALS (OPC) PRIVATE LIMITEDTRACXN · PUBLIC DATA
Brand ORGYNE PHARMACEUTICALS (OPC) PRIVATE LIMITED · Legal entity Orgyne Pharmaceuticals (OPC) Private Limited
Explore the complete profile of ORGYNE PHARMACEUTICALS (OPC) PRIVATE LIMITED, including financials and company filings, contact details, and much more on Tracxn.
Total Funding
Latest Round
—
Revenue
Valuation
Funding Rounds
—
Employees
—
Stage
—
HQ
—
Founded
2019
Source: Tracxn (public profile) · joined to MCA on CIN U24230TG2019OPC135766
Quick facts
Registered office
—
NIC code
24230
Statutory auditor
Awaiting ADT-1 / AOC-4 extraction
Registered email
—
Section
Pharmaceuticals & Chemicals
ROC
—
Website
Class · sub-category
Private
Incorporation · Last AGM
— · —
Directors
LockedVS
Vikram Singh Rathore
Director8.5y · Chennai · DIN 6857164
RK
Rajesh Kumar Sharma
Managing Director3.8y · Bengaluru · DIN 9282457
PN
Priya Nair
Additional Director1.9y · Hyderabad · DIN 8391504
AD
Anita Desai
Managing Director8.4y · New Delhi · DIN 9916658
Get the full board of directors
Directors, DINs & appointment history for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
MCA Filings
Locked| Form | FY | Filed | Due | Delay | Status |
|---|---|---|---|---|---|
| AOC-4 | FY2024-25 | 30 Oct 2024 | 30 Oct 2024 | 0d | filed |
| MGT-7 | FY2024-25 | 27 Nov 2024 | 29 Nov 2024 | 0d | filed |
| AOC-4 | FY2023-24 | 30 Oct 2023 | 30 Oct 2023 | +28d | filed |
| MGT-7 | FY2023-24 | 20 Nov 2023 | 29 Nov 2023 | 0d | filed |
| AOC-4 | FY2022-23 | 30 Oct 2022 | 30 Oct 2022 | 0d | filed |
| MGT-7 | FY2022-23 | 26 Nov 2022 | 29 Nov 2022 | 0d | filed |
Get financial statements & other filing documents
Full MCA filing history for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Charges
Locked| Charge ID | Holder | Amount | Created | Status |
|---|---|---|---|---|
| 199404260 | Axis Bank Ltd(Bank) | ₹3.59 Cr | 19 Sep 2020 | Satisfied |
| 694071085 | Axis Bank Ltd(Bank) | ₹14.66 Cr | 12 Mar 2021 | Open |
| 185935821 | HDFC Bank Ltd(Bank) | ₹1.82 Cr | 12 Mar 2023 | Open |
| 587633838 | ICICI Bank Ltd(Bank) | ₹23.76 Cr | 12 Mar 2021 | Open |
See registered charges & lenders
Charge IDs, lenders & amounts for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Financial Performance
Locked| FY | Revenue | PAT | Net Worth | Total Assets | Employees |
|---|---|---|---|---|---|
| FY2024-25 | ₹28.76 Cr | ₹1.54 Cr | ₹25.38 Cr | ₹43.32 Cr | 346 |
| FY2023-24 | ₹23.03 Cr | ₹92.67 L | ₹14.31 Cr | ₹31.72 Cr | 85 |
| FY2022-23 | ₹20.28 Cr | ₹1.52 Cr | ₹18.05 Cr | ₹32.43 Cr | 291 |
| FY2021-22 | ₹22.26 Cr | ₹1.51 Cr | ₹18.95 Cr | ₹28.17 Cr | 42 |
Gain deeper financial insights of this entity
Audited financials & ratios for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Detailed Financials
Locked| Line item | FY2024-25 | FY2023-24 | FY2022-23 | FY2021-22 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue from operations | ₹28.76 Cr | ₹23.03 Cr | ₹20.28 Cr | ₹22.26 Cr |
| Other income | ₹77.11 L | ₹12.49 L | ₹29.74 L | ₹75.97 L |
| Total income | ₹29.54 Cr | ₹23.16 Cr | ₹20.58 Cr | ₹23.02 Cr |
| Total expenses | ₹27.56 Cr | ₹21.97 Cr | ₹18.63 Cr | ₹21.09 Cr |
| Profit before tax | ₹2.00 Cr | ₹1.20 Cr | ₹1.97 Cr | ₹1.96 Cr |
| Profit / (Loss) after tax | ₹1.54 Cr | ₹92.67 L | ₹1.52 Cr | ₹1.51 Cr |
| Balance sheet | ||||
| Equity / Net worth | ₹25.38 Cr | ₹14.31 Cr | ₹18.05 Cr | ₹18.95 Cr |
| Borrowings | ₹3.60 Cr | ₹8.26 Cr | ₹7.79 Cr | ₹2.36 Cr |
| Current liabilities | ₹8.70 Cr | ₹10.25 Cr | ₹7.64 Cr | ₹2.77 Cr |
| Total liabilities | ₹17.94 Cr | ₹17.41 Cr | ₹14.38 Cr | ₹9.22 Cr |
| Current assets | ₹17.92 Cr | ₹12.38 Cr | ₹15.42 Cr | ₹16.31 Cr |
| Cash & equivalents | ₹2.33 Cr | ₹2.35 Cr | ₹6.16 Cr | ₹3.56 Cr |
| Total assets | ₹43.32 Cr | ₹31.72 Cr | ₹32.43 Cr | ₹28.17 Cr |
| Employees | 346 | 85 | 291 | 42 |
Gain deeper financial insights of this entity
Audited financials & ratios for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Compounded Annual Growth Rate
Locked| Metric | Latest value | 1Y CAGR | 3Y CAGR | 5Y CAGR |
|---|---|---|---|---|
| Revenue | ₹28.76 Cr | +27.0% | +23.8% | +2.5% |
| Profit after Tax | ₹1.54 Cr | +19.3% | +27.3% | +11.7% |
| Net Worth | ₹25.38 Cr | -4.7% | +25.8% | -2.8% |
| Employees | 346 | +14.7% | +3.1% | +8.1% |
Gain deeper financial insights of this entity
Audited financials & ratios for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Financial Ratios
Locked| FY | Revenue | PAT | PAT margin | Rev growth | ROE | ROA | D/E | Rev/emp |
|---|---|---|---|---|---|---|---|---|
| FY2024-25 | ₹28.76 Cr | ₹1.54 Cr | +5.36% | +25.66% | +6.07% | +3.56% | 0.14 | ₹8.31 L |
| FY2023-24 | ₹23.03 Cr | ₹92.67 L | +4.02% | +30.38% | +6.48% | +2.92% | 0.58 | ₹27.10 L |
| FY2022-23 | ₹20.28 Cr | ₹1.52 Cr | +7.49% | +10.26% | +8.41% | +4.68% | 0.43 | ₹6.97 L |
| FY2021-22 | ₹22.26 Cr | ₹1.51 Cr | +6.78% | -13.35% | +7.96% | +5.36% | 0.12 | ₹53.01 L |
Gain deeper financial insights of this entity
Audited financials & ratios for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Financial Summary & Charts
- Income Statement, Balance Sheet, Cashflow
- Profitability, Liquidity & Growth Ratios
- Audited Financial Statement (AOC-4)
Cap Table & Shareholding
Locked| Category | Shareholders | Shares held | % |
|---|---|---|---|
| Promoters | 2 | 1,04,93,944 | 73.33% |
| Institutional Investors | 2 | 4,33,033 | 3.03% |
| Public & Others | 44 | 33,83,933 | 23.65% |
See the full shareholding pattern
Promoter, institutional & public holding for Orgyne Pharmaceuticals (OPC) Private Limited.
What you'll get
- Incorporation Documents
- Change in Directors & Designated Partner
- Board Resolutions
- Financial Statements & Annual Filings
- Charge Documents (Summary)
Peer Benchmark
313 peersMetricThis companyCohort medianCohort P75Quartile
Revenue (latest FY)
—
PAT (latest FY)
—
Employees
—
—
—
—
Paid-up capital
—
Compliance Health
63
96
96
Bottom quartile · P0
External data sources
7 plannedGSTIN Registrations
GST portal
Per-state GSTINs + GSTR-1/3B filing cadence + turnover bracket. PAN-keyed scrape.
MSME Payment Delays
MSME-1 form
Half-yearly disclosure of payments delayed beyond 45 days to MSME suppliers.
Related Party Transactions
AOC-4 schedule
Counterparty, nature, transaction value. Inter-company loans, sales, royalty.
Credit Ratings
CRISIL / ICRA / CARE feeds
Long-term + short-term ratings, with rationale on rating actions.
Trademarks
IP India Trademark Registry
Applied, registered, opposed. Class numbers + status.
Patents
IP India Patent Registry
Applications and grants. Inventor names + filing dates.
Legal Cases
eCourts + Indian Kanoon
Ongoing + past litigations the entity is party to.
Each source is wired as a separate ingestion adapter behind the scraper. Live status flips per CIN as records land.
FAQs about Orgyne Pharmaceuticals (OPC) Private Limited
When was Orgyne Pharmaceuticals (OPC) Private Limited incorporated?
Orgyne Pharmaceuticals (OPC) Private Limited was incorporated in 2019. Its CIN is U24230TG2019OPC135766 and it is registered with the relevant Registrar of Companies.
Where is Orgyne Pharmaceuticals (OPC) Private Limited located?
Orgyne Pharmaceuticals (OPC) Private Limited is headquartered in Telangana.
What sector does Orgyne Pharmaceuticals (OPC) Private Limited operate in?
Orgyne Pharmaceuticals (OPC) Private Limited operates in the Pharmaceuticals & Chemicals sector (NIC code 24230), classified as Indian Non-Govt Company.
Who are the directors of Orgyne Pharmaceuticals (OPC) Private Limited?
Director details for Orgyne Pharmaceuticals (OPC) Private Limited have not yet been extracted from MGT-7 filings.
What is the paid-up capital of Orgyne Pharmaceuticals (OPC) Private Limited?
Orgyne Pharmaceuticals (OPC) Private Limited has authorized capital of — and paid-up capital of —.
Does Orgyne Pharmaceuticals (OPC) Private Limited have any open charges?
Orgyne Pharmaceuticals (OPC) Private Limited has no open MCA-registered charges on record.
What is Orgyne Pharmaceuticals (OPC) Private Limited's Compliance Health Score?
RegisterKaro's Compliance Health Score for Orgyne Pharmaceuticals (OPC) Private Limited is 30/100 (grade F), based on 9 weighted signals across MCA filings, charges, directors, capital, and overall status. 3 of 9 signals passed.